| Bioactivity | Mopidamol (RA 233), a derivative of Dipyridamole (HY-B0312), is a phosphodiesterase inhibitor. RA-233 can be used for non-small cell lung cancer (N-SCLC) research[1][2]. |
| CAS | 13665-88-8 |
| Formula | C19H31N7O4 |
| Molar Mass | 421.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Eliasson R, Bygdeman S. Effect of dipyridamole and two pyrimido-pyrimidine derivatives on the kinetics of human platelet aggregation and on platelet adhesiveness. Scand J Clin Lab Invest. 1969 Sep;24(2):145-51. [2]. Zacharski LR, et al. Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188. J Natl Cancer Inst. 1988 Mar 16;80(2):90-7. |